AG
CYTK icon

Advisor Group’s Cytokinetics CYTK Stock Holding History

Advisor Group’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		$1K Buy
68
+16
+31% +$164 ﹤0.01% 5120
2019
Q3 		$1K Buy
+52
New +$653 ﹤0.01% 5094
2018
Q2 		– Sell
-150
Closed -$1K – 4947
2018
Q1 		$1K Sell
150
-150
-50% -$1.29K ﹤0.01% 4805
2017
Q4 		$2K Sell
300
-400
-57% -$4.54K ﹤0.01% 4669
2017
Q3 		$10K Sell
700
-423
-38% -$5.78K ﹤0.01% 3954
2017
Q2 		$14K Buy
1,123
+400
+55% +$5.56K ﹤0.01% 3724
2017
Q1 		$9K Hold
723
– – ﹤0.01% 3830
2016
Q4 		$9K Hold
723
– – ﹤0.01% 3658
2016
Q3 		$7K Hold
723
– – ﹤0.01% 3745
2016
Q2 		$6K Buy
+723
New +$5.93K ﹤0.01% 3693

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $290M AUM 143.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Advisor Group's CYTK Position: Q4 2019 in Review

Advisor Group increased its Cytokinetics (CYTK) stake by 31% in Q4 2019, buying an estimated $164 and bringing the position to 68 shares worth $1K. The position accounts for ﹤0.01% of the portfolio, ranked #5120.

Advisor Group first reported a position in CYTK in Q2 2016 and has held it in 10 quarters since. The position peaked at $14K in Q2 2017. 142 funds tracked by Wall St. Rank hold CYTK as of Q4 2019.

  • Advisor Group held 68 shares of Cytokinetics worth $1K as of Q4 2019.
  • Advisor Group bought 16 Cytokinetics shares in Q4 2019, an estimated $164.
  • Cytokinetics made up ﹤0.01% of Advisor Group's portfolio in Q4 2019, its #5120 holding.
  • Advisor Group first reported a position in Cytokinetics in Q2 2016 and has held it in 10 quarters since.
  • Advisor Group's Cytokinetics position peaked at $14K in Q2 2017.
  • 142 funds tracked by Wall St. Rank held Cytokinetics as of Q4 2019.

Based on Advisor Group's 13F filing for Q4 2019, filed 12 Feb 2020.